Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors

BACKGROUND: Osimertinib exhibits good efficacy in patients with T790M-positive non-small cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). Compared with the clinical trials, in real-world clinical practice, osimertinib must...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Dis
Main Authors: Kato, Yasuhiro, Hosomi, Yukio, Watanabe, Kageaki, Yomota, Makiko, Kawai, Shoko, Okuma, Yusuke, Kubota, Kaoru, Seike, Masahiro, Gemma, Akihiko, Okamura, Tatsuru
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6626778/
https://ncbi.nlm.nih.gov/pubmed/31372272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2019.06.03
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados